Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 10/20 | 0.41 |
| ▸ | HTR1A | P08908 | 10/20 | 0.40 |
| ▸ | HTR7 | P34969 | 10/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30874959 | 0.78 | CNR2 (0.37) | — | |
| SCHEMBL30874863 | 0.76 | ALDH1A1 (0.35) | — | |
| SCHEMBL30874827 | 0.76 | — | — | |
| SCHEMBL30874907 | 0.76 | PLAU (0.36) | — | |
| SCHEMBL30874828 | 0.75 | DPP4 (0.40) | DPP4HTR1AHTR7DPP9 | |
| SCHEMBL30874864 | 0.75 | VNN1 (0.47) | DPP4HTR1AHTR7DPP9 | |
| SCHEMBL30874874 | 0.74 | VNN1 (0.44) | DPP4HTR1AHTR7DPP9 | |
| SCHEMBL30874895 | 0.73 | TRHR (0.41) | — | |
| SCHEMBL30874950 | 0.73 | DPP4 (0.42) | DPP4HTR1AHTR7DPP9 | |
| SCHEMBL30874841 | 0.73 | CFD (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117956985-A | Inhibitors of glycogen synthase 1 (GYS 1) and methods of use thereof | 梅兹治疗公司 | 2024-04-30 | — | — | CN | disclosed |
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230104740-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2023-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS2, GYS1, PYGL | DPP4 3092/4885HTR1A 2664/4885HTR7 4171/4885 |
| US-20230104740-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | GYS2, GYS1, PYGL | DPP4 3092/4885HTR1A 2664/4885HTR7 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.